Todd Kinsella

Todd Kinsella joined Vividion in 2017 as Vice President of Translational and Development Sciences. Todd supports all stages of Vividion’s therapeutic pipeline from target identification, validation, drug discovery and the translational biology interface connecting pre-clinical programs and development.

Prior to joining Vividion, Todd served as Vice President of Research at Rigel Pharmaceuticals with over 18 years of experience in small molecule and antibody-based drug discovery. He was instrumental in establishing Rigel’s original flagship technology for discovering novel drugable targets. He has founded and served as head of numerous departments within Rigel, and led key drug discovery programs within target discovery-immunology, virology, muscle, metabolism, vascular biology and immuno-oncology.

Todd received his BS in Molecular and Cellular Biology from the University of Arizona and PhD in Molecular Pharmacology from Stanford University. He is an author of 15 published articles and an inventor on 26 issued patents.